TY - JOUR
T1 - Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018
AU - Spitaleri, Giosafat
AU - Lupón, Josep
AU - Domingo, Mar
AU - Santiago-Vacas, Evelyn
AU - Codina, Pau
AU - Zamora, Elisabet
AU - Cediel, Germán
AU - Santesmases, Javier
AU - Diez-Quevedo, Crisanto
AU - Troya, Maria Isabel
AU - Boldo, Maria
AU - Altmir, Salvador
AU - Alonso, Nuria
AU - González, Beatriz
AU - Núñez, Julio
AU - Bayes-Genis, Antoni
N1 - Publisher Copyright:
© 2021, The Author(s).
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1/12
Y1 - 2021/1/12
N2 - To assess mortality trends at 1 and 3 years from 2001 to 2018 in a real-life cohort of HF outpatients from different etiologies with depressed and preserved LVEF. A total of 2368 consecutive patients with HF (mean age 66.4 ± 12.9 years, 71% men, 15.4% with preserved LVEF) admitted to a HF clinic from August 2001 to September 2018 were included in the study. Patients were divided into five quintiles (Q) according to the period of admission. Trends for all-cause and cardiovascular mortality from Q1 to Q5 were assessed by linear regression. Patients with LVEF < 50% had a progressive decrease in the rates of all-cause and cardiovascular death at 1 year (12.1% in Q1 to 6.5% in Q5, p = 0.003; and 8.4% in Q1 to 3.8% in Q5, p = 0.007, respectively) and 3 years (30.5% in Q1 to 17.0% in Q5, p = 0.003; and 23.9% in Q1 to 9.8% in Q5, p = 0.003, respectively). These trends remained significant after adjusting for clinical characteristics and risk. No significant trend in mortality was observed in patients with LVEF ≥ 50%. In a cohort of real-life ambulatory patients with HF, mortality progressively declined in patients with LVEF < 50%, but the same trend was not observed in patients with preserved LVEF.
AB - To assess mortality trends at 1 and 3 years from 2001 to 2018 in a real-life cohort of HF outpatients from different etiologies with depressed and preserved LVEF. A total of 2368 consecutive patients with HF (mean age 66.4 ± 12.9 years, 71% men, 15.4% with preserved LVEF) admitted to a HF clinic from August 2001 to September 2018 were included in the study. Patients were divided into five quintiles (Q) according to the period of admission. Trends for all-cause and cardiovascular mortality from Q1 to Q5 were assessed by linear regression. Patients with LVEF < 50% had a progressive decrease in the rates of all-cause and cardiovascular death at 1 year (12.1% in Q1 to 6.5% in Q5, p = 0.003; and 8.4% in Q1 to 3.8% in Q5, p = 0.007, respectively) and 3 years (30.5% in Q1 to 17.0% in Q5, p = 0.003; and 23.9% in Q1 to 9.8% in Q5, p = 0.003, respectively). These trends remained significant after adjusting for clinical characteristics and risk. No significant trend in mortality was observed in patients with LVEF ≥ 50%. In a cohort of real-life ambulatory patients with HF, mortality progressively declined in patients with LVEF < 50%, but the same trend was not observed in patients with preserved LVEF.
UR - http://www.scopus.com/inward/record.url?scp=85099248831&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/556451f4-2548-3c5f-acca-e6eeb9e5b837/
U2 - 10.1038/s41598-020-79926-3
DO - 10.1038/s41598-020-79926-3
M3 - Artículo
C2 - 33436787
AN - SCOPUS:85099248831
SN - 2045-2322
VL - 11
SP - 732
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 732
ER -